Modulation of paraoxonase 1 and 3 expression after moderate exercise training in the rat

Journal of Lipid Research

Volumn 50, Issue 10, 2009, Pages 2036-2045

  Romani, Rita ^a   De Medio, Gianna Evelina ^a   Di Tullio, Simona ^b   Lapalombella, Rosa ^b   Pirisinu, Irene ^a   Margonato, Vittoria ^c   Veicsteinas, Arsenio ^c,d   Marini, Marina ^b   Rosi, Gabriella ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Arylesterase; Carboxylesterase; Lactonase; Membrane phospholipids; Mild exercise training; Protein expression; Real time PCR

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 3; MESSENGER RNA; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME RELEASE; EXERCISE; GENE EXPRESSION; LIPID COMPOSITION; LIVER MEMBRANE; LIVER MICROSOME; MALE; NONHUMAN; PHYSICAL STRESS; PRIORITY JOURNAL; RAT; UPREGULATION;

ANIMALS; ARYLDIALKYLPHOSPHATASE; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MALE; MICROSOMES, LIVER; MOTOR ACTIVITY; PHOSPHOLIPIDS; POLYMERASE CHAIN REACTION; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70350374060     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800493-JLR200     Document Type: Article

References (48)

1. Kurl, S., J. A. Laukkanen, L. Niskanen, R. Rauramaa, T. P. Tuomainen, J. Sivenius, and J. T. Salonen. 2005. Cardiac power during exercise and the risk of stroke in men. Stroke. 36: 820-824.
2. Haskell, W. L., I. M. Lee, P. R. Pate, K. E. Powell, S. N. Blair, B. A. Franklin, C. A. Macera, G. W. Heath, P. D. Thompson, and A. Bauman. 2007. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med. Sci. Sports Exerc. 39: 1423-1434.
3. Di Loreto, C., C. Fanelli, P. Lucidi, G. Murdolo, A. De Cicco, N. Parlanti, A. Ranchelli, C. Fatone, C. Taglioni, F. Santeusanio, et al. 2005. Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care. 28: 1295-1302.
4. Leaf, D. A. 2003. The effect of physical exercise on reverse cholesterol transport. Metabolism. 52: 950-957.
5. Parthasarathy, S., J. Barnett, and L. G. Fong. 1990. High density lipoprotein inhibits the oxidative modifi cation of low-density lipoprotein. Biochim. Biophys. Acta. 1044: 275-283.
6. Shih, D. M., Y. R. Xia, X. P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535.
7. Durrington, P. N., B. Mackness, and M. I. Mackness. 2001. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 473-480.
8. Rozenberg, O., M. Rosenblat, R. Coleman, D. M. Shih, and M. Aviram. 2003. Paraoxonase (PON1) defi ciency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34: 774-784.
9. Tward, A., Y. R. Xia, X. P. Wang, Y. S. Shi, C. Park, L. W. Castellani, A. J. Lusis, and D. M. Shih. 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 106: 484-490.
10. Rozenberg, O., D. M. Shih, and M. Aviram. 2005. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis. 181: 9-18.
11. Primo-Parmo, S. L., R. C. Sorenson, J. Teiber, and B. N. La Du. 1996. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 33: 498-507.
12. Draganov, D. I., and B. N. La Du. 2004. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch. Pharmacol. 369: 78-88.
13. Draganov, D. I., J. F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B. N. La Du. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46: 1239-1247.
14. Draganov, D. I., P. L. Stetson, C. E. Watson, S. S. Billecke, and B. N. La Du. 2000. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low-density lipoprotein against oxidation. J. Biol. Chem. 275: 33435-33442.
15. Harel, M., A. Aharoni, L. Gaidukov, B. Brumshtein, O. Khersonsky, R. Meged, H. Dvir, R. B. Ravelli, A. McCarthy, L. Toker, et al. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11: 412-419.
16. Rodriguez Esparragon, F., Y. Hernandez Trujillo, A. Macias Reyes, E. Hernandez Ortega, A. Medina, and J. C. Rodriguez Perez. 2006. Concerning the signifi cance of paraoxonase-1 and SR-B1 genes in atherosclerosis. Rev. Esp. Cardiol. 59: 154-164.
17. Teiber, J. F., D. I. Draganov, and B. N. La Du. 2003. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol. 66: 887-896.
18. Pla, A., L. Rodrigo, A. F. Hernández, F. Gil, and O. Lopez. 2007. Effect of metal ions and calcium on purifi ed PON1 and PON3 from rat liver. Chem. Biol. Interact. 167: 63-70.
19. Draganov, D. I. 2007. Human PON3, effects beyond the HDL: clues from Human PON3 transgenic mice. Circ. Res. 100: 1104-1105.
20. Ng, C. J., D. J. Wadleigh, A. Gangopadhyay, S. Hama, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2001. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modifi cation of low density lipoprotein. J. Biol. Chem. 276: 44444-44449.
21. Reddy, S. T., D. J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D. M. Shih, A. J. Lusis, M. Navab, and A. M. Fogelman. 2001. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21: 542-547.
22. Shih, D. M., X. P. Xia, X. P. Wang, S. S. Wang, N. Bourquard, A. M. Fogelman, A. J. Lusis, and S. T. Reddy. 2007. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ. Res. 100: 1200-1207.
23. Rodrigo, L., F. Gil, A. F. Hernandez, O. Lopez, and A. Pla. 2003. Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties. Biochem. J. 376: 261-268.
24. James, R. W., and S. P. Deakin. 2004. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic. Biol. Med. 37: 1986-1994.
25. Tomás, M., R. Elosua, M. Senti, L. Molina, J. Vila, R. Anglada, M. Fito, M. I. Covas, and J. Marrugat. 2002. Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity. J. Lipid Res. 43: 713-720.
26. Pawlowska, D., J. Moniuszko-Jakoniuk, and M. Soltys. 1985. Parathion-methyl effect on the activity of hydrolytic enzymes after single physical exercise in rats. Pol. J. Pharmacol. Pharm. 37: 629-638.
27. Clarkson, P. M. 1995. Antioxidants and physical performance. Crit. Rev. Food Sci. Nutr. 35: 131-141.
28. Aviram, M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, R. C. Bisgaier, R. S. Newton, and B. N. La Du. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26: 892-904.
29. Marini, M., R. Lapalombella, V. Margonato, R. Ronchi, M. Samaja, C. Scapin, L. Gorza, T. Maraldi, P. Carinci, C. Ventura, et al. 2007. Mild exercise training, cardioprotection and stress gene profile. Eur. J. Appl. Physiol. 99: 503-510.
30. Deakin, S., I. Leviev, M. Gomaraschi, L. Calabresi, G. Franceschini, and R. W. James. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277: 4301-4308.
31. Draganov, D. I., K. M. Sass, C. E. Watson, C. L. Bisgaier, S. T. Reddy, J. F. Teiber, and N. B. La Du. 2002. The N-terminal sequences of human paraoxonase-1 (PON1) and paraoxonase-3 (PON3) are responsible for their different translocation and secretion. Circulation. 106(II): 123.
32. Shamir, R., C. Hartman, R. Karry, E. Pavlotzky, R. Eliakim, J. Lachter, A. Suissa, and M. Aviram. 2005. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic. Biol. Med. 39: 336-344.
33. American Physiological Society. 2006. Resource Book for the Design of Animal Exercise Protocols. Accessed August 25, 2008, at http://www.the-aps.org/pa/action/exercise/book.pdf.
34. Li, B., M. Sedlacek, I. Manoharan, R. Boopathy, E. G. Duysen, P. Masson, and O. Lockridge. 2005. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 70: 1673-1684.
35. Gil, F., A. Pla, M. G. Golzalvo, A. F. Hernández, and E. Villanueva. 1993. Partial purification of paraoxonase from rat liver. Chem. Biol. Interact. 87: 69-75.
36. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193: 265-275.
37. Gan, K. N., A. Smolen, H. W. Eckerson, and B. N. La Du. 1991. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19: 100-106.
38. Billecke, S., D. Draganov, R. Counsell, P. Stetson, C. Watson, C. Hsu, and B. N. La Du. 2000. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28: 1335-1342.
39. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25: 402-408.
40. Gaiti, A., G. Goracci, G. E. De Medio, and G. Porcellati. 1972. Enzymic synthesis of plasmalogen and O-alkyl glycerolipid by base-exchange reaction in the rat brain. FEBS Lett. 27: 116-120.
41. Binaglia, L., G. Goracci, G. Porcellati, R. Roberti, and H. Woelk. 1973. The synthesis of coline and ethanolamine phosphoglycerides in neuronal and glial cells of rabbit in vitro. J. Neurochem. 21: 1067-1082.
42. Aviram, M. 2004. Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases. Free Radic. Biol. Med. 37: 1301-1303.
43. Gonzalvo, M. C., F. Gil, A. F. Hernandez, L. Rodrigo, E. Villanueva, and A. Pla. 1998. Human liver paraoxonase (PON1): subcellular distribution and characterization. J. Biochem. Mol. Toxicol. 12: 61-69.
44. Ferrè, N., J. Camps, M. Cabrè, A. Paul, and J. Joven. 2001. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism. 50: 997-1000.
45. Oda, M. N., J. Bielicki, T. Berger, and T. M. Forte. 2001. Cysteine substitutions in apolipoprotein A-I primary structure modulate paraoxonase activity. Biochemistry. 40: 1710-1718.
46. Navab, M., S. Y. Hama, G. P. Hough, C. C. Hedrick, R. Sorenson, B. N. La Du, J. A. Kobashigawa, G. C. Fonarow, J. A. Berliner, H. Laks, et al. 1998. High density associated enzymes: their role in vascular biology. Curr. Opin. Lipidol. 9: 449-456.
47. Rosenblat, M., D. Draganov, C. E. Watson, C. L. Bisgaier, B. N. La Du, and M. Aviram. 2003. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23: 468-474.
48. Ng, C. J., N. Bourquard, S. Y. Hama, D. Shih, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2007. Adenovirus-mediated expression of human paraoxonase 3 protects against toprogression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27: 1368-1374.